Research shows ampion™ gene regulation mimics the anti-inflammatory effects of steroids, but without adverse effects

Englewood, colo., april 19, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that ampio's lead drug candidate, ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids.
AMPE Ratings Summary
AMPE Quant Ranking